Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | SN30000 |
Synonyms | |
Therapy Description |
SN30000 (CEN-209) is a hypoxia-activated prodrug that causes DNA damage within hypoxic regions of tumors, potentially providing antineoplastic activity (PMID: 20732963, PMID: 31131698). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SN30000 | CEN-209 | SN30000 (CEN-209) is a hypoxia-activated prodrug that causes DNA damage within hypoxic regions of tumors, potentially providing antineoplastic activity (PMID: 20732963, PMID: 31131698). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PALB2 dec exp | triple-receptor negative breast cancer | sensitive | SN30000 | Preclinical | Actionable | In a preclinical study, knockdown of PALB2 enhanced growth inhibition by SN30000 in triple-negative breast cancer cell lines in culture (PMID: 25193512). | 25193512 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|